186 related articles for article (PubMed ID: 20977885)
1. Isolation of tumorigenic circulating melanoma cells.
Ma J; Lin JY; Alloo A; Wilson BJ; Schatton T; Zhan Q; Murphy GF; Waaga-Gasser AM; Gasser M; Stephen Hodi F; Frank NY; Frank MH
Biochem Biophys Res Commun; 2010 Nov; 402(4):711-7. PubMed ID: 20977885
[TBL] [Abstract][Full Text] [Related]
2. Identification of cells initiating human melanomas.
Schatton T; Murphy GF; Frank NY; Yamaura K; Waaga-Gasser AM; Gasser M; Zhan Q; Jordan S; Duncan LM; Weishaupt C; Fuhlbrigge RC; Kupper TS; Sayegh MH; Frank MH
Nature; 2008 Jan; 451(7176):345-9. PubMed ID: 18202660
[TBL] [Abstract][Full Text] [Related]
3. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized.
Quintana E; Shackleton M; Foster HR; Fullen DR; Sabel MS; Johnson TM; Morrison SJ
Cancer Cell; 2010 Nov; 18(5):510-23. PubMed ID: 21075313
[TBL] [Abstract][Full Text] [Related]
4. Modulation of T-cell activation by malignant melanoma initiating cells.
Schatton T; Schütte U; Frank NY; Zhan Q; Hoerning A; Robles SC; Zhou J; Hodi FS; Spagnoli GC; Murphy GF; Frank MH
Cancer Res; 2010 Jan; 70(2):697-708. PubMed ID: 20068175
[TBL] [Abstract][Full Text] [Related]
5. Application of a filtration- and isolation-by-size technique for the detection of circulating tumor cells in cutaneous melanoma.
De Giorgi V; Pinzani P; Salvianti F; Panelos J; Paglierani M; Janowska A; Grazzini M; Wechsler J; Orlando C; Santucci M; Lotti T; Pazzagli M; Massi D
J Invest Dermatol; 2010 Oct; 130(10):2440-7. PubMed ID: 20535130
[TBL] [Abstract][Full Text] [Related]
6. Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs.
Vishnoi M; Boral D; Liu H; Sprouse ML; Yin W; Goswami-Sewell D; Tetzlaff MT; Davies MA; Oliva ICG; Marchetti D
Cancer Res; 2018 Sep; 78(18):5349-5362. PubMed ID: 30026332
[TBL] [Abstract][Full Text] [Related]
7. Circulating Melanoma Cell Subpopulations: Their Heterogeneity and Differential Responses to Treatment.
Gray ES; Reid AL; Bowyer S; Calapre L; Siew K; Pearce R; Cowell L; Frank MH; Millward M; Ziman M
J Invest Dermatol; 2015 Aug; 135(8):2040-2048. PubMed ID: 25830652
[TBL] [Abstract][Full Text] [Related]
8. Tumor initiation in human malignant melanoma and potential cancer therapies.
Ma J; Frank MH
Anticancer Agents Med Chem; 2010 Feb; 10(2):131-6. PubMed ID: 20184545
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells in Stage IV Melanoma Patients.
Hall CS; Ross M; Bowman Bauldry JB; Upshaw J; Karhade MG; Royal R; Patel S; Lucci A
J Am Coll Surg; 2018 Jul; 227(1):116-124. PubMed ID: 29746918
[TBL] [Abstract][Full Text] [Related]
10. Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
Koyanagi K; O'Day SJ; Boasberg P; Atkins MB; Wang HJ; Gonzalez R; Lewis K; Thompson JA; Anderson CM; Lutzky J; Amatruda TT; Hersh E; Richards J; Weber JS; Hoon DS
Clin Cancer Res; 2010 Apr; 16(8):2402-8. PubMed ID: 20371696
[TBL] [Abstract][Full Text] [Related]
11. PMN-MDSCs Enhance CTC Metastatic Properties through Reciprocal Interactions via ROS/Notch/Nodal Signaling.
Sprouse ML; Welte T; Boral D; Liu HN; Yin W; Vishnoi M; Goswami-Sewell D; Li L; Pei G; Jia P; Glitza-Oliva IC; Marchetti D
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31003475
[TBL] [Abstract][Full Text] [Related]
12. High Number of Circulating Tumor Cells Predicts Poor Survival of Cutaneous Melanoma Patients in China.
Li J; Fu W; Zhang W; Li P
Med Sci Monit; 2018 Jan; 24():324-331. PubMed ID: 29337932
[TBL] [Abstract][Full Text] [Related]
13. Circulating tumor cells as prognostic biomarkers in cutaneous melanoma patients.
Kiyohara E; Hata K; Lam S; Hoon DS
Methods Mol Biol; 2014; 1102():513-22. PubMed ID: 24258996
[TBL] [Abstract][Full Text] [Related]
14. The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.
Linley AJ; Mathieu MG; Miles AK; Rees RC; McArdle SE; Regad T
J Biol Chem; 2012 Apr; 287(17):13633-43. PubMed ID: 22393060
[TBL] [Abstract][Full Text] [Related]
15. Genetically determined ABCB5 functionality correlates with pigmentation phenotype and melanoma risk.
Lin JY; Zhang M; Schatton T; Wilson BJ; Alloo A; Ma J; Qureshi AA; Frank NY; Han J; Frank MH
Biochem Biophys Res Commun; 2013 Jul; 436(3):536-42. PubMed ID: 23770371
[TBL] [Abstract][Full Text] [Related]
16. Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population.
Fukunaga-Kalabis M; Martinez G; Nguyen TK; Kim D; Santiago-Walker A; Roesch A; Herlyn M
Oncogene; 2010 Nov; 29(46):6115-24. PubMed ID: 20729912
[TBL] [Abstract][Full Text] [Related]
17. Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis.
Chiu CG; Nakamura Y; Chong KK; Huang SK; Kawas NP; Triche T; Elashoff D; Kiyohara E; Irie RF; Morton DL; Hoon DS
Clin Chem; 2014 Jun; 60(6):873-85. PubMed ID: 24718909
[TBL] [Abstract][Full Text] [Related]
18. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
19. Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
Luo Y; Ellis LZ; Dallaglio K; Takeda M; Robinson WA; Robinson SE; Liu W; Lewis KD; McCarter MD; Gonzalez R; Norris DA; Roop DR; Spritz RA; Ahn NG; Fujita M
J Invest Dermatol; 2012 Oct; 132(10):2440-2450. PubMed ID: 22622430
[TBL] [Abstract][Full Text] [Related]
20. The influence of nano-TiO2 on metabolic activity, cytotoxicity and ABCB5 mRNA expression in WM-266-4 human metastatic melanoma cell line.
Zdravkovic B; Zdravkovic TP; Zdravkovic M; Strukelj B; Ferk P
J BUON; 2019; 24(1):338-346. PubMed ID: 30941990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
